Company Profile
Processa Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- PCSA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.30 USD (+5.02%)
Close
Last updated: August 6, 2026
8.03M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PCSA closed up 5.02% at $2.30. No new same-company headline was identified in the current news window.
Company overview
Business overview
Processa Pharmaceuticals is a development-stage company focused on improving the safety and efficacy of existing oncology drugs through next-generation formulations and combinations. Its story centers on making known medicines more usable in difficult cancer settings.
Geographic Base and Sector Classification
Processa is headquartered in the United States and listed on NASDAQ. It sits in small-cap biopharmaceutical development.
Business Model Characteristics
The business depends on clinical progress, formulation strategy, and the ability to advance a narrow pipeline with limited resources. Investors typically watch proof-of-concept data and partnership or financing activity.
Position Within the Biotechnology Landscape
Processa occupies a niche oncology-development position within biotech. It is a small-cap story where the commercial value depends on whether modified therapies can truly improve outcomes.
Future catalysts
Processa’s catalysts are its rare-disease and oncology programs, especially any development update that clarifies which assets still matter. The company needs a cleaner clinical path.
Recent news
- 01
- 02
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Source: Processa Pharmaceuticals
- 03
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Source: Processa Pharmaceuticals
- 04
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Source: Processa Pharmaceuticals
- 05
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Source: Processa Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Processa Pharmaceuticals (PCSA)?
Processa Pharmaceuticals (PCSA) most recently closed at 2.30 USD, a +5.02% move versus the previous session.
What is the market cap of Processa Pharmaceuticals (PCSA)?
Processa Pharmaceuticals currently has a market capitalization of 8.03M USD on BioPharmSignal.
What does Processa Pharmaceuticals do?
Processa Pharmaceuticals is a development-stage company focused on improving the safety and efficacy of existing oncology drugs through next-generation formulations and combinations. Its story centers on making known medicines more usable in difficult cancer settings.
On which exchange is PCSA stock listed?
Processa Pharmaceuticals (PCSA) is associated with NASDAQ, United States, Biopharma.
What is Processa?
Processa’s catalysts are its rare-disease and oncology programs, especially any development update that clarifies which assets still matter.
Which conditions is Processa Pharmaceuticals targeting with Processa?
Processa Pharmaceuticals is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Processa Pharmaceuticals describe recent progress with Processa?
Processa’s catalysts are its rare-disease and oncology programs, especially any development update that clarifies which assets still matter.
What is Pharmaceuticals?
Processa Pharmaceuticals is a development-stage company focused on improving the safety and efficacy of existing oncology drugs through next-generation formulations and combinations.